Currently, numerous natural and synthetic KDM1A inhibitors have been identified in the last decades (Zheng et al., 2016b; Li Y. et al., 2019; Dai et al., 2020; Jia et al., 2020), and some of which are currently undergoing clinical assessment for the treatment of acute myeloid leukemia (AML), small cell lung cancer (SCLC) as well as some other solid tumors (Mohammad et al., 2015; Maes et al., 2018). The gene discussed is KDM1A; the disease is small cell lung carcinoma.